Drugs / Prof-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04734405 | Oct 2019 → Nov 2022 | vulvovaginal candidiasis | ProFem GmbH | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prof-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04734405 ↗ |
| Route | Topical | “Topically administered ProF-001” NCT04734405 ↗ |